A novel angiopoietin-derived peptide displays anti-angiogenic activity and inhibits tumour-induced and retinal neovascularization

G. M. Palmer, Z. Tiran, Z. Z. Zhou, M. E. Capozzi, W. Park, C. Coletta, A. Pyriochou, Y. Kliger, O. Levy, I. Borukhov, M. W. Dewhirst, G. Rotman, J. S. Penn, Andreas Papapetropoulos

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Background and purpose: Pathological angiogenesis is associated with various human diseases, such as cancer, autoimmune diseases and retinopathy. The angiopoietin (Ang)-Tie2 system plays critical roles in several steps of angiogenic remodelling. Here, we have investigated the anti-angiogenic effect of a novel angiopoietin-derived peptide. Experimental approach: Using computational methods, we identified peptides from helical segments within angiopoietins, which were predicted to inhibit their activity. These peptides were tested using biochemical methods and models of angiogenesis. The peptide with best efficacy, A11, was selected for further characterization as an anti-angiogenic compound. Key results: The potent anti-angiogenic activity of A11 was demonstrated in a multicellular assay of angiogenesis and in the chorioallantoic membrane model. A11 bound to angiopoietins and reduced the binding of Ang-2 to Tie2. A11 was also significantly reduced vascular density in a model of tumour-induced angiogenesis. Its ability to inhibit Ang-2 but not Ang-1-induced endothelial cell migration, and to down-regulate Tie2 levels in tumour microvessels, suggests that A11 targets the Ang-Tie2 pathway. In a rat model of oxygen-induced retinopathy, A11 strongly inhibited retinal angiogenesis. Moreover, combination of A11 with an anti-VEGF antibody showed a trend for further inhibition of angiogenesis, suggesting an additive effect. Conclusions and implications: Our results indicate that A11 is a potent anti-angiogenic compound, through modulation of the Ang-Tie2 system, underlining its potential as a therapeutic agent for the treatment of ocular and tumour neovascularization, as well as other pathological conditions that are dependent on angiogenesis.

Original languageEnglish (US)
Pages (from-to)1891-1903
Number of pages13
JournalBritish Journal of Pharmacology
Volume165
Issue number6
DOIs
StatePublished - Mar 1 2012
Externally publishedYes

Fingerprint

Angiopoietins
Retinal Neovascularization
Peptides
Angiopoietin-2
Neoplasms
Pathologic Neovascularization
Angiopoietin-1
Chorioallantoic Membrane
Microvessels
Vascular Endothelial Growth Factor A
Autoimmune Diseases
Cell Movement
Blood Vessels
Anti-Idiotypic Antibodies
Down-Regulation
Endothelial Cells
Oxygen

Keywords

  • angiogenesis
  • angiopoietin
  • apoptosis
  • retinopathy
  • therapeutic peptide
  • Tie2
  • tumour
  • xenograft

ASJC Scopus subject areas

  • Pharmacology

Cite this

A novel angiopoietin-derived peptide displays anti-angiogenic activity and inhibits tumour-induced and retinal neovascularization. / Palmer, G. M.; Tiran, Z.; Zhou, Z. Z.; Capozzi, M. E.; Park, W.; Coletta, C.; Pyriochou, A.; Kliger, Y.; Levy, O.; Borukhov, I.; Dewhirst, M. W.; Rotman, G.; Penn, J. S.; Papapetropoulos, Andreas.

In: British Journal of Pharmacology, Vol. 165, No. 6, 01.03.2012, p. 1891-1903.

Research output: Contribution to journalArticle

Palmer, GM, Tiran, Z, Zhou, ZZ, Capozzi, ME, Park, W, Coletta, C, Pyriochou, A, Kliger, Y, Levy, O, Borukhov, I, Dewhirst, MW, Rotman, G, Penn, JS & Papapetropoulos, A 2012, 'A novel angiopoietin-derived peptide displays anti-angiogenic activity and inhibits tumour-induced and retinal neovascularization', British Journal of Pharmacology, vol. 165, no. 6, pp. 1891-1903. https://doi.org/10.1111/j.1476-5381.2011.01677.x
Palmer, G. M. ; Tiran, Z. ; Zhou, Z. Z. ; Capozzi, M. E. ; Park, W. ; Coletta, C. ; Pyriochou, A. ; Kliger, Y. ; Levy, O. ; Borukhov, I. ; Dewhirst, M. W. ; Rotman, G. ; Penn, J. S. ; Papapetropoulos, Andreas. / A novel angiopoietin-derived peptide displays anti-angiogenic activity and inhibits tumour-induced and retinal neovascularization. In: British Journal of Pharmacology. 2012 ; Vol. 165, No. 6. pp. 1891-1903.
@article{f6886fe8e4ee49169aa5c870cfdd92f5,
title = "A novel angiopoietin-derived peptide displays anti-angiogenic activity and inhibits tumour-induced and retinal neovascularization",
abstract = "Background and purpose: Pathological angiogenesis is associated with various human diseases, such as cancer, autoimmune diseases and retinopathy. The angiopoietin (Ang)-Tie2 system plays critical roles in several steps of angiogenic remodelling. Here, we have investigated the anti-angiogenic effect of a novel angiopoietin-derived peptide. Experimental approach: Using computational methods, we identified peptides from helical segments within angiopoietins, which were predicted to inhibit their activity. These peptides were tested using biochemical methods and models of angiogenesis. The peptide with best efficacy, A11, was selected for further characterization as an anti-angiogenic compound. Key results: The potent anti-angiogenic activity of A11 was demonstrated in a multicellular assay of angiogenesis and in the chorioallantoic membrane model. A11 bound to angiopoietins and reduced the binding of Ang-2 to Tie2. A11 was also significantly reduced vascular density in a model of tumour-induced angiogenesis. Its ability to inhibit Ang-2 but not Ang-1-induced endothelial cell migration, and to down-regulate Tie2 levels in tumour microvessels, suggests that A11 targets the Ang-Tie2 pathway. In a rat model of oxygen-induced retinopathy, A11 strongly inhibited retinal angiogenesis. Moreover, combination of A11 with an anti-VEGF antibody showed a trend for further inhibition of angiogenesis, suggesting an additive effect. Conclusions and implications: Our results indicate that A11 is a potent anti-angiogenic compound, through modulation of the Ang-Tie2 system, underlining its potential as a therapeutic agent for the treatment of ocular and tumour neovascularization, as well as other pathological conditions that are dependent on angiogenesis.",
keywords = "angiogenesis, angiopoietin, apoptosis, retinopathy, therapeutic peptide, Tie2, tumour, xenograft",
author = "Palmer, {G. M.} and Z. Tiran and Zhou, {Z. Z.} and Capozzi, {M. E.} and W. Park and C. Coletta and A. Pyriochou and Y. Kliger and O. Levy and I. Borukhov and Dewhirst, {M. W.} and G. Rotman and Penn, {J. S.} and Andreas Papapetropoulos",
year = "2012",
month = "3",
day = "1",
doi = "10.1111/j.1476-5381.2011.01677.x",
language = "English (US)",
volume = "165",
pages = "1891--1903",
journal = "British Journal of Pharmacology",
issn = "0007-1188",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - A novel angiopoietin-derived peptide displays anti-angiogenic activity and inhibits tumour-induced and retinal neovascularization

AU - Palmer, G. M.

AU - Tiran, Z.

AU - Zhou, Z. Z.

AU - Capozzi, M. E.

AU - Park, W.

AU - Coletta, C.

AU - Pyriochou, A.

AU - Kliger, Y.

AU - Levy, O.

AU - Borukhov, I.

AU - Dewhirst, M. W.

AU - Rotman, G.

AU - Penn, J. S.

AU - Papapetropoulos, Andreas

PY - 2012/3/1

Y1 - 2012/3/1

N2 - Background and purpose: Pathological angiogenesis is associated with various human diseases, such as cancer, autoimmune diseases and retinopathy. The angiopoietin (Ang)-Tie2 system plays critical roles in several steps of angiogenic remodelling. Here, we have investigated the anti-angiogenic effect of a novel angiopoietin-derived peptide. Experimental approach: Using computational methods, we identified peptides from helical segments within angiopoietins, which were predicted to inhibit their activity. These peptides were tested using biochemical methods and models of angiogenesis. The peptide with best efficacy, A11, was selected for further characterization as an anti-angiogenic compound. Key results: The potent anti-angiogenic activity of A11 was demonstrated in a multicellular assay of angiogenesis and in the chorioallantoic membrane model. A11 bound to angiopoietins and reduced the binding of Ang-2 to Tie2. A11 was also significantly reduced vascular density in a model of tumour-induced angiogenesis. Its ability to inhibit Ang-2 but not Ang-1-induced endothelial cell migration, and to down-regulate Tie2 levels in tumour microvessels, suggests that A11 targets the Ang-Tie2 pathway. In a rat model of oxygen-induced retinopathy, A11 strongly inhibited retinal angiogenesis. Moreover, combination of A11 with an anti-VEGF antibody showed a trend for further inhibition of angiogenesis, suggesting an additive effect. Conclusions and implications: Our results indicate that A11 is a potent anti-angiogenic compound, through modulation of the Ang-Tie2 system, underlining its potential as a therapeutic agent for the treatment of ocular and tumour neovascularization, as well as other pathological conditions that are dependent on angiogenesis.

AB - Background and purpose: Pathological angiogenesis is associated with various human diseases, such as cancer, autoimmune diseases and retinopathy. The angiopoietin (Ang)-Tie2 system plays critical roles in several steps of angiogenic remodelling. Here, we have investigated the anti-angiogenic effect of a novel angiopoietin-derived peptide. Experimental approach: Using computational methods, we identified peptides from helical segments within angiopoietins, which were predicted to inhibit their activity. These peptides were tested using biochemical methods and models of angiogenesis. The peptide with best efficacy, A11, was selected for further characterization as an anti-angiogenic compound. Key results: The potent anti-angiogenic activity of A11 was demonstrated in a multicellular assay of angiogenesis and in the chorioallantoic membrane model. A11 bound to angiopoietins and reduced the binding of Ang-2 to Tie2. A11 was also significantly reduced vascular density in a model of tumour-induced angiogenesis. Its ability to inhibit Ang-2 but not Ang-1-induced endothelial cell migration, and to down-regulate Tie2 levels in tumour microvessels, suggests that A11 targets the Ang-Tie2 pathway. In a rat model of oxygen-induced retinopathy, A11 strongly inhibited retinal angiogenesis. Moreover, combination of A11 with an anti-VEGF antibody showed a trend for further inhibition of angiogenesis, suggesting an additive effect. Conclusions and implications: Our results indicate that A11 is a potent anti-angiogenic compound, through modulation of the Ang-Tie2 system, underlining its potential as a therapeutic agent for the treatment of ocular and tumour neovascularization, as well as other pathological conditions that are dependent on angiogenesis.

KW - angiogenesis

KW - angiopoietin

KW - apoptosis

KW - retinopathy

KW - therapeutic peptide

KW - Tie2

KW - tumour

KW - xenograft

UR - http://www.scopus.com/inward/record.url?scp=84863138369&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863138369&partnerID=8YFLogxK

U2 - 10.1111/j.1476-5381.2011.01677.x

DO - 10.1111/j.1476-5381.2011.01677.x

M3 - Article

C2 - 21943108

AN - SCOPUS:84863138369

VL - 165

SP - 1891

EP - 1903

JO - British Journal of Pharmacology

JF - British Journal of Pharmacology

SN - 0007-1188

IS - 6

ER -